American Society Of Clinical Oncology Highlights
Executive Summary
Provenge cancer vaccine improves survival: Final three-year analysis of Dendreon's prostate cancer vaccine Provenge Phase III D9901 study shows a median survival of 25.9 months for Provenge compared to 21.4 months for placebo, a statistically significant 4.5 month improvement (p=0.01) that "was not due to any imbalances in the patient population," Dendreon reports May 14 at ASCO. An analysis of imbalances between immunotherapy and placebo populations showed no difference in subsequent use of chemotherapy after progression. "In addition, 34% of patients receiving Provenge were alive at 36 months compared to 11% of patients receiving placebo (p=0.0046)." The therapeutic vaccine was well-tolerated among the 127 men with hormone-refractory prostate cancer. An earlier interim analysis of the study did not show significance for time to progression. Provenge failed to meet the final endpoint of time to progression in a separate Phase III trial (D9902A). Dendreon has another pivotal Phase III trial (D9902B) underway, under a special protocol assessment with FDA...
You may also be interested in...
Provenge Survival Data Plagued by Small Study Size, Post hoc Analysis
The Cellular, Tissue and Gene Therapies Advisory Committee's favorable recommendation on the efficacy of Dendreon's Provenge could give FDA greater confidence in accepting the post hoc survival analysis and approving the cancer vaccine
Provenge Survival Data Plagued by Small Study Size, Post hoc Analysis
The Cellular, Tissue and Gene Therapies Advisory Committee's favorable recommendation on the efficacy of Dendreon's Provenge could give FDA greater confidence in accepting the post hoc survival analysis and approving the cancer vaccine
Dendreon’s Provenge Cancer Vaccine Shows “Substantial Efficacy” – Cmte.
Although not convinced that existing data fully prove the efficacy of Dendreon's Provenge, a majority of FDA's Cellular, Tissue and Gene Therapies Advisory Committee agreed during a March 29 meeting that there is "substantial evidence" the biologic is effective and should be approved